GeoVax Labs, Inc. — Q3 2015 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2015. GeoVax is a clinical-stage biotechnology company developing vaccines for HIV, Ebola, and Marburg. It had no approved products or commercialization capability; reported revenue was from NIH grants.
Financial performance and position
| Metric | Q3 2015 | Q3 2014 | Nine months 2015 | Nine months 2014 |
|---|---|---|---|---|
| Grant revenue | $93,130 | $322,086 | $268,028 | $659,867 |
| Research and development expense | $378,521 | $425,498 | $1,166,803 | $1,344,560 |
| General and administrative expense | $335,932 | $411,814 | $1,102,262 | $1,128,478 |
| Total operating expenses | $714,453 | $837,312 | $2,269,065 | $2,473,038 |
| Net loss | $619,899 | $514,515 | $1,996,556 | $1,809,970 |
| Loss per share | $0.02 | $0.02 | $0.06 | $0.07 |
- Cash and liquidity: Cash was $1.82 million at September 30, 2015, versus $1.10 million at December 31, 2014. Working capital was $1.78 million, up from $1.04 million. Current liabilities were $118,221.
- Cash flow, nine months: Operating activities used $1.94 million; investing activities used $15,850; financing activities provided $2.68 million, principally from the Series C preferred-stock financing. Cash increased by $719,386.
- Capital and debt: No long-term debt or committed credit lines were reported. Stockholders’ equity was $1.88 million. Accumulated deficit was $31.8 million.
- Margins: The filing does not present conventional gross-margin measures; grant revenue is recognized as related costs are incurred.
Material changes versus comparable periods
- Grant revenue declined 71% in Q3 and 59% for the nine-month period, reflecting lower grant-supported activity and expenditure timing.
- Operating expenses fell 15% in Q3 and 8% year to date, but the net loss increased 20% in Q3 and 10% year to date, as the reduction in grant revenue more than offset lower expenses.
- Research and development expense decreased 11% in Q3 and 13% year to date. General and administrative expense decreased 18% in Q3 and 2% year to date.
- February’s Series C financing raised $3.0 million gross and approximately $2.7 million net. The Series C conversion price was adjusted to $0.142 per share; related warrant exercise prices were also reset.
Outlook, risks and notable items
- Management said cash resources and grant commitments were expected to fund planned operations through the first quarter of 2016. The filing cites substantial doubt about the company’s ability to continue as a going concern beyond that point absent additional funding; funding may not be available on favorable terms or at all. Failure to raise funds could delay, scale back, or end programs.
- At September 30, $260,522 of approved NIH grant funds remained available, expected to be recognized through the first half of 2016. The company also reported pursuing further grants, clinical-trial support, philanthropic support, and possible equity financing.
- Management expected a NIH-funded Phase 1 HIV protein-boost trial to begin in late 2015, while seeking funding to advance the preventive HIV vaccine to Phase 2b. Ebola/Marburg preclinical animal studies were ongoing; management anticipated potential human trials in late 2016 or early 2017. These plans depend on funding, research outcomes, and regulatory progress.
- Potential dilution is significant: 79.1 million common shares were reserved for preferred-stock conversion, warrants, and equity plans, compared with 31.95 million common shares issued and outstanding. This includes 56.4 million warrants; exercise is not assured. The one-year Series E warrants, exercisable at $0.142, could provide approximately $2.4 million if fully exercised and were due to expire February 27, 2016.
- Lease payments and firm purchase commitments totaled approximately $222,000. No legal proceedings were reported; management reported no material change in previously disclosed risk factors. Disclosure controls were assessed as effective.
Important facts for investors to verify
- Whether GeoVax obtained funding after the stated first-quarter 2016 cash runway, and the resulting impact on the going-concern assessment and research programs.
- Whether the HIV protein-boost trial and planned HIV and Ebola/Marburg development milestones proceeded as described.
- Current grant availability, timing, and conditions, including whether further government or clinical-trial support was secured.
- Actual conversion and warrant-exercise activity, updated share count, and the effect of the preferred-stock and warrant price-adjustment provisions on dilution.
- Whether reported grant revenue and expenses continued to fluctuate with NIH-funded research activity.